Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing. We use our novel, next-generation CRISPR genome-editing technology to armor allogeneic, or off-the-shelf, cell therapies for potentially improved antitumor activity. We believe that allogeneic cell therapies have the potential to meet significant unmet needs for patients. To deliver on our mission, we are advancing our pipeline of genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies and CAR-NK cell therapies for solid tumors.

Leadership team

Executive leadership team

Rachel Haurwitz photo

Rachel Haurwitz, PhD

President and chief executive officer

Steven Kanner photo

Steve Kanner, PhD

Chief scientific officer

Tim Kelly photo

Tim Kelly

Chief technology officer

Ruhi Khan photo

Ruhi Khan

Chief business officer

Barbara McClung photo

Barbara McClung, JD

Chief legal officer and corporate secretary

Jason O’Byrne photo

Jason O’Byrne

Chief financial officer

reigin zawadzki photo

Reigin Zawadzki

Chief people officer

Partnering and alliances

Caribou has an extensive CRISPR technology IP portfolio, including an exclusive license from The Regents of the University of California and the University of Vienna to the foundational CRISPR-Cas9 IP invented by Jennifer Doudna, Emmanuelle Charpentier, and their colleagues. Caribou licenses this CRISPR-Cas9 IP and certain of its own Cas9 IP to other companies for use in multiple market sectors including but not limited to research tools, transgenic research animals, internal research, diagnostics, and industrial biotechnology. For information regarding partnering and licensing, email licensing@cariboubio.com

Contact us about partnering and licensing